We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.03 | 0.07% | 42.30 | 42.99 | 41.9103 | 42.24 | 16,786,015 | 00:51:38 |
By Austen Hufford
The Food and Drug Administration said Monday that it approved Bristol-Myers Squibb Co.'s Empliciti to treat multiple myeloma, a form of blood cancer. The FDA approved Empliciti to be used in combination with two other FDA-approved treatments, Janssen Biotech's Darzalex and Celgene Corp.'s Revlimid.
In a 646-participant clinical trial, those treated with the three-drug cocktail took longer to relapse and had a higher chance of tumor shrinkage than those treated with the two-drug therapy.
Multiple myeloma is a type of blood cancer that occurs in infection-fighting white blood cells found in the bone marrow. The National Cancer Institute estimates there will be 26,850 new multiple myeloma cases and 11,240 related deaths in the U.S. this year. Empliciti activates the body's own immune system to attack and destroy multiple myeloma cells.
Bristol-Myers and AbbVie Inc. are codeveloping the drug, with Bristol-Myers responsible for marketing and commercial activities.
Earlier this month, Darzalex was also approved to treat the disease. Special designations from the FDA for both Empliciti and Darzalex allowed them to go through the review process faster than normal. The FDA granted the drugs breakthrough therapy designations, priority reviews and orphan-drug designations.
Write to Austen Hufford at austen.hufford@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 30, 2015 11:53 ET (16:53 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions